When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

Sixty years after the discovery of the Epstein–Barr virus (EBV), Münz discusses new developments in the immunobiology of the first discovered human tumour virus, including vaccines and the role ...

New research from the University of Pittsburgh School of Medicine and La Jolla Institute for Immunology, published today in ...

An analysis of mpox virus genomes from individuals infected between 2018 and 2023 has provided insights into how the virus ...

Merck & Co has entered into a worldwide licensing deal with Opko Health’s ModeX Therapeutics unit for a vaccine candidate against Epstein-Barr virus (EBV) that could be worth up to $922.5 ...